1. Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism & related disorders. 2016;22 Suppl 1:S29-33.
2. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: A review of the literature. Movement Disorders. 2007;22(15):2141-8.
3. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. Journal of neurology, neurosurgery, and psychiatry. 2014;85(8):925-9.
4. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. Journal of neurology, neurosurgery, and psychiatry. 2014;85(8):925-9.
5. Coakeley S, Cho SS, Koshimori Y, Rusjan P, Ghadery C, Kim J, et al. [18 F] AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Structure and Function. 2018;223(2):589-95.
6. Hammes J, Bischof GN, Giehl K, Faber J, Drzezga A, Klockgether T, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Movement disorders : official journal of the Movement Disorder Society. 2017;32(1):170-1.
7. Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016;87(22):2309-16.
8. Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, et al. Tau imaging with [(18) F]THK-5351 in progressive supranuclear palsy. European journal of neurology. 2017;24(1):130-6.
9. Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J, et al. [(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Frontiers in aging neuroscience. 2017;9:440.
10. Cho H, Choi JY, Hwang MS, Lee SH, Ryu YH, Lee MS, et al. Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy. Movement disorders : official journal of the Movement Disorder Society. 2017;32(1):134-40.
11. Whitwell JL, Tosakulwong N, Schwarz CG, Botha H, Senjem ML, Spychalla AJ, et al. MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement disorders : official journal of the Movement Disorder Society. 2019;34(1):105-13.
12. Koga S, Ono M, Sahara N, Higuchi M, Dickson DW. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology. Movement disorders : official journal of the Movement Disorder Society. 2017;32(6):884-92.
13. Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of neurology. 2015;78(5):787-800.
14. Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous Sr MD, et al. 18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of neurology. 2017;82(4):622-34.
15. Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, et al. (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's research & therapy. 2019;11(1):13.
16. Hammes J, Bischof GN, Giehl K, Faber J, Drzezga A, Klockgether T, et al. Elevated in vivo [18F]‐AV‐1451 uptake in a patient with progressive supranuclear palsy. Movement Disorders. 2017;32(1):170-1.